Rivastigmine for HIV-Associated Neurocognitive Disorders?

Rivastigmine improved information processing speed, but not other cognitive functions, in a small cohort of patients with HIV-associated neurocognitive disorders.

As HIV infection progresses, symptoms of HIV-associated dementia and its milder forms, such as asymptomatic neurocognitive impairment and mild neurocognitive disorder, may develop. Combined antiretroviral therapy (cART) has decreased the incidence of HIV-associated dementia, but the prevalence has increased due to the increased life span of HIV-infected patients. Specific treatment of these disorders remains elusive.

In this partially manufacturer-funded study, researchers enrolled 17 aviremic HIV-infected patients with mild HIV-associated neurocognitive disorders (HAND) in a randomized, double-blind, placebo-controlled, crossover study to receive oral rivastigmine at a dosage of up to 12 mg/day for 20 weeks and placebo for 20 weeks before o…

Reviewing Author

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders

Jaime Toro, MD

Disclosures

Editorial BoardsMultiple Sclerosis and Related Disorders